FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.63 USD
-0.02 (-0.432%)
About
ceo
Mr. William D. Baird III, M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.2seventybio.com
exchange
NASDAQ
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
CIK
0001860782
ISIN
US9013841070
CUSIP
901384107
Address
60 Binney Street
Phone
339 499 9300
Country
US
Employee
274
IPO Date
Nov 3, 2021
Key Executives
